Edoxaban
When a changing supply pattern becomes difficult to ignore
14 April 2026: highlighted to iethico subscribers | 1 September 2026: DHSC Tier 2 Medicine Supply Notification
Medicine supply disruption rarely begins with one definitive event. More often, the evidence develops gradually. A notification appears in one country, another emerges elsewhere, and different strengths or presentations may be affected at different times. Individually, these events can appear isolated. Over time, however, the character of the evidence can change.
For iethico subscribers, Edoxaban reached that point in April 2026. On 14 April, Edoxaban was highlighted in our subscriber intelligence following a developing pattern of international supply disruption.
Almost five months later, on 1 September 2026, the Department of Health and Social Care issued a Tier 2 Medicine Supply Notification for Edoxaban (Lixiana) 15mg tablets. The notification reported that Lixiana 15mg tablets were out of stock until mid-September. Alternative DOACs were stated to remain available and able to support increased demand, while unlicensed Edoxaban 15mg tablets could also be sourced.
** When did isolated events become a signal?**
International supply notifications involving Edoxaban were already visible during 2025. Those earlier events were intermittent. It would be too simplistic to look backwards from September 2026 and treat every earlier notification as part of the same developing event.
What changed in early 2026 was the persistence of the evidence. Supply notifications began appearing repeatedly across successive months. By February and March, the pattern was becoming more sustained. In April, Edoxaban was highlighted to iethico subscribers.
What happened next?
The pattern continued through May, June, July and August. Then, on 1 September, DHSC issued its Tier 2 Medicine Supply Notification for Lixiana 15mg tablets.
There were approximately 140 days between the iethico subscriber signal and the formal UK notification. That interval created something scarce in medicine supply: time to investigate, understand exposure, watch whether the pattern resolved or persisted, and consider where additional demand might move if UK supply became constrained.
A market shaped by changing value
Edoxaban’s position within NHS prescribing did not develop by accident. On 19 January 2022, NHS England published national commissioning recommendations following the national procurement of direct-acting oral anticoagulants. Edoxaban became the preferred option where clinically appropriate because it was the most cost-effective of the four recommended DOACs at the time.
The market then changed. Following loss of exclusivity and sufficient generic availability, NHS England updated its recommendations on 6 September 2024. Generic Apixaban and generic Rivaroxaban became the joint best-value options, with Edoxaban ranked second. Clinical appropriateness for the individual patient remained central to treatment choice.
The movement is visible in NHS medicines data. Secondary-care Edoxaban volume rose substantially after the 2022 recommendation. As the value hierarchy changed, Edoxaban began to decline, while Apixaban increased and Rivaroxaban rose particularly strongly during 2025. The chart indexes each medicine to its own January 2022 level so that the direction of change can be compared without obscuring the smaller Edoxaban market.
Figure 1. Monthly secondary-care SCMD volume, indexed to January 2022 = 100. Source: NHS SCMD data analysed by iethico.
**What does that mean for suppliers? **
For the NHS, responding to generic competition and directing prescribing towards better-value medicines can generate substantial savings while maintaining access to clinically appropriate treatment. For suppliers, the same change has to be translated into production forecasts, manufacturing capacity, inventory and distribution.
A medicine that becomes the preferred option may have to accommodate rapid growth in demand. If the economics change again, demand may move elsewhere, while the previous preferred medicine continues to support a substantial established patient population. Supply planning therefore has to respond to a market whose value signals can change faster than physical capacity, stock and distribution can be adjusted.
When an alternative is needed
The September Edoxaban notification states that alternative DOACs remain available and can support increased demand. There is no reason to assume that DHSC reached that conclusion without assessing the relevant alternatives.
But there is another view of the market. During 2026, presentations of both Apixaban and Rivaroxaban have appeared in the Drug Tariff price-concession system. More importantly for iethico, pharmacies within our procurement panel were also reporting periods when they could not purchase some Apixaban and Rivaroxaban products.
That does not mean those medicines were universally unavailable across the UK, or that they could not absorb additional Edoxaban demand. It shows why national availability and pharmacy-level access are not always the same thing. A medicine can remain available nationally while individual pharmacies experience difficulty obtaining it through their normal supply routes.
The wider resilience question
The DOAC market shows how effectively procurement can respond to changing value. It also shows the challenge this creates for supply planning. In 2022, Edoxaban was the preferred best-value option. By September 2024, generic Apixaban and Rivaroxaban had moved ahead of it. NHS medicines data shows demand responding to those changes.
By September 2026, Edoxaban had become a formally recognised UK supply issue, while parts of the Apixaban and Rivaroxaban markets had also shown signs of procurement difficulty. These observations do not establish a common cause. They do make the resilience of the whole therapeutic market relevant, rather than the resilience of one medicine in isolation.
**The signal lesson **
Edoxaban did not move from an uneventful market to a UK Tier 2 notification overnight. International supply evidence developed over time. By April, the pattern had changed sufficiently for Edoxaban to be highlighted to iethico subscribers. The evidence persisted, and on 1 September DHSC issued its Tier 2 notification for Lixiana 15mg tablets.
For iethico subscribers, Edoxaban had been on the radar since 14 April. The value of that earlier visibility was not simply knowing sooner. It was having more time to understand what was changing, what might be exposed, and what the wider market might be asked to absorb.
Sources and notes
NHS England, Commissioning recommendations for national procurement for direct-acting oral anticoagulant(s) (DOACs), first published 19 January 2022; operational note last updated 6 September 2024.
NHS England, Thousands of lives saved by the NHS thanks to rapid rollout of blood thinners, November 2023.
Community Pharmacy England, Medicine Supply Notification: Edoxaban (Lixiana) 15mg tablets, MSN/2026/042, 1 September 2026.
NHS Secondary Care Medicines Data (SCMD), analysed by iethico. iethico subscriber and pharmacy procurement panel observations are proprietary iethico evidence.